Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
about
Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysisCan knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid TumorsPharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL studyEvaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trialDermatologic events from EGFR inhibitors: the issue of the missing patient voice.Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.MicroRNA-133a downregulated EGFR expression in human non-small cell lung cancer cells via AKT/ERK signaling
P2860
Q21133732-0E20C1CC-71ED-4721-88F7-835A6BDA9BDBQ26859144-F9276C7D-7A41-4DDF-8AF1-C1E740E6EA99Q28553729-14BF7F6B-AC95-4992-B059-271F5ABE3372Q33613666-AE5E5ACD-2B8D-4FF3-9A3D-D152E069D27EQ34658247-5365160E-91B9-4A5E-99B1-6B8E6A231F6AQ35081379-ACDA613F-8CB9-4FE0-B408-0E25FECDAD9CQ35749286-EA1C23F7-7E41-4456-94CC-BC2860110BA3Q36368641-23A1A688-1EBE-4473-BC48-AC1D086C5AA1Q37541523-94CBA601-7ED9-461A-A953-B1EA89971A76Q37709570-F85F6343-F68A-4099-A133-52F0E3868757Q38101885-F7A79F89-04CA-41C2-A682-343A00423453Q38190857-7B045641-A053-4C25-9B28-54C4C0B1774AQ38937228-4C0910CA-0673-4DA3-A152-CE1392E6B59CQ41027999-A7A0DEC8-D27A-4E60-B240-BF720AEE3910Q43515674-2DDE02D4-F2C2-4BA4-B9B4-B9BBACE53B95Q47969048-10396D47-1B53-4B96-B038-D501218A04CDQ54520157-640BA896-9047-4569-B199-A494686A9FDFQ58573308-84AECB74-2D69-4872-9430-EDA1BC857735
P2860
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Erlotinib 'dosing-to-rash': a ...... ed non-small cell lung cancer.
@ast
Erlotinib 'dosing-to-rash': a ...... ed non-small cell lung cancer.
@en
type
label
Erlotinib 'dosing-to-rash': a ...... ed non-small cell lung cancer.
@ast
Erlotinib 'dosing-to-rash': a ...... ed non-small cell lung cancer.
@en
prefLabel
Erlotinib 'dosing-to-rash': a ...... ed non-small cell lung cancer.
@ast
Erlotinib 'dosing-to-rash': a ...... ed non-small cell lung cancer.
@en
P2093
P2860
P356
P1476
Erlotinib 'dosing-to-rash': a ...... ed non-small cell lung cancer.
@en
P2093
A W Tolcher
E K Rowinsky
G Schwartz
K Papadopoulos
P2860
P2888
P304
P356
10.1038/BJC.2011.332
P407
P577
2011-08-30T00:00:00Z
P5875
P6179
1017243670